Athenex Inc.'s (ATNX) shares more than halved in value on Monday morning after the biopharmaceutical company received a completed response letter from FDA regarding its oral paclitaxel plus encequidar for the treatment of metastatic breast cancer.
ATNX is currently trading at $5.77, down $6.33 or 52.28%, on the Nasdaq.
Athenex, a biopharmaceutical company dedicated to the development of novel therapies for the treatment of cancer, announced that the FDA issued a complete response letter for the company's New Drug Application for oral paclitaxel plus encequidar for the treatment of metastatic breast cancer.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.